1. Home
  2. TBPH vs ACNB Comparison

TBPH vs ACNB Comparison

Compare TBPH & ACNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • ACNB
  • Stock Information
  • Founded
  • TBPH 2013
  • ACNB 1857
  • Country
  • TBPH United States
  • ACNB United States
  • Employees
  • TBPH N/A
  • ACNB N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • ACNB Major Banks
  • Sector
  • TBPH Health Care
  • ACNB Finance
  • Exchange
  • TBPH Nasdaq
  • ACNB Nasdaq
  • Market Cap
  • TBPH 464.5M
  • ACNB 405.4M
  • IPO Year
  • TBPH N/A
  • ACNB N/A
  • Fundamental
  • Price
  • TBPH $8.91
  • ACNB $43.99
  • Analyst Decision
  • TBPH Buy
  • ACNB Strong Buy
  • Analyst Count
  • TBPH 3
  • ACNB 4
  • Target Price
  • TBPH $11.33
  • ACNB $50.00
  • AVG Volume (30 Days)
  • TBPH 268.3K
  • ACNB 25.5K
  • Earning Date
  • TBPH 05-08-2025
  • ACNB 04-24-2025
  • Dividend Yield
  • TBPH N/A
  • ACNB 3.10%
  • EPS Growth
  • TBPH N/A
  • ACNB N/A
  • EPS
  • TBPH N/A
  • ACNB 2.79
  • Revenue
  • TBPH $65,266,000.00
  • ACNB $113,448,000.00
  • Revenue This Year
  • TBPH $51.09
  • ACNB $35.43
  • Revenue Next Year
  • TBPH N/A
  • ACNB $6.64
  • P/E Ratio
  • TBPH N/A
  • ACNB $15.56
  • Revenue Growth
  • TBPH 6.11
  • ACNB 8.66
  • 52 Week Low
  • TBPH $7.44
  • ACNB $30.24
  • 52 Week High
  • TBPH $10.90
  • ACNB $50.72
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 40.95
  • ACNB 65.99
  • Support Level
  • TBPH $8.69
  • ACNB $41.91
  • Resistance Level
  • TBPH $10.55
  • ACNB $43.39
  • Average True Range (ATR)
  • TBPH 0.38
  • ACNB 1.06
  • MACD
  • TBPH -0.12
  • ACNB 0.20
  • Stochastic Oscillator
  • TBPH 12.06
  • ACNB 90.36

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About ACNB ACNB Corporation

ACNB Corp provides banking, insurance, and financial services to businesses and consumers, through its wholly-owned subsidiaries, ACNB Bank and ACNB Insurance Services, Inc. The corporation has two reporting segments; the Banking segment which generates the majority of the revenue from banking and wealth management services, including trust and retail brokerage, and ACNB Insurance Services segment which offers a broad range of property and casualty, life and health insurance to both commercial and individual clients.

Share on Social Networks: